PREPARATION AND PROPERTIES OF MURINE ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES RECOGNIZING PRIMARY RABBIT POLYCLONAL ANTIBODIES AGAINST MORPHINE DERIVATIVES

Anti-idiotypic antibodies (Ab2), according to the network theory of Jerne, are second-generation immunoglobulins that are produced against the idiotype of an antibody to a specific antigen. Despite the large number of works devoted to the study of the properties of these proteins, their role in the regulation of the immune system is not fully known. It may consist in maintaining or blocking a minimal immune response to the antigen. The study of Ab2 is of great practical and scientific importance. The special properties of Ab2, namely, the ability to partially reproduce the structure of the primary antigen and, upon immunization, induce the appearance of tertiary antibodies, which, like first-generation antibodies, can bind to the antigen, have found application in the development of Ab2-based vaccines, in particular, for the treatment of tumors. In view of the presence of a number of limitations on research related to psychoactive substances, the development of Ab2- based vaccines against drug addiction also seems promising. To example, anti-idiotypic antibodies obtained for this purpose possessing a cocaine-like structure are described in the literature. In this work, murine monoclonal anti-idiotypic antibodies (mAb2) mimicking the structure of various morphine derivatives were obtained. Rabbit polyclonal antibodies to the 6-hemisuccinyl derivative of morphine conjugated with bovine serum albumin isolated by affinity chromatography were used as primary antibodies for immunization. Four hybridoma clones were obtained as a result of the fusion of immunized mice lymphocytes with mouse Sp2/0 mouse myeloma cells by the Milstein-Köhler method. After growth in animals, mAb2 produced by hybridoma cells were affinity purified. We investigated the physicochemical and antigenic properties of the isolated antibodies. It was shown that the obtained mAb2 differ in immunological specificity, competing in different degree with morphine derivatives for binding to first-generation antibodies. We tested the possibility of using the obtained mAb2 as antigen analogues in the solid-phase enzyme-linked immunosorbent assay to determine the titer of primary antibodies against morphine in the blood serum of laboratory animals immunized with morphine derivatives. Based on the obtained anti-idiotypic antibodies, it is proposed to develop test systems to determine the serum opiate-specific antibodies in people after specific vaccination for therapeutic or prophylactic purposes to avoid the use of drugs as antigens immobilized on the solid phase in the analysis

Creation of a recombinant Komagataella phaffii strain, a producer of proteinase K from Tritirachium album

The objects of the study were recombinant clones of Komagataella phaffii K51 carrying the heterologous proteinase K (PK-w) gene from Tritirachium album integrated into their genome as well as samples of recombinant proteinase K isolated from these clones. The aims of this work were i) to determine whether it is possible to create recombinant K. phaffii K51 clones overexpressing functionally active proteinase K from T. album and ii) to analyze the enzymatic activity of the resulting recombinant enzyme. The following methods were used: computational analysis of primary structure of the proteinase K gene, molecular biological methods (PCR, electrophoresis of DNA in an agarose gel, electrophoresis of proteins in an SDS polyacrylamide gel under denaturing conditions, spectrophotometry, and quantitative assays of protease activity), and genetic engineering techniques (cloning and selection of genes in bacterial cells Escherichia coli TOP10 and in the methylotrophic yeast K. phaffii K51). The gene encoding natural proteinase K (PK-w) was designed and optimized for expression in K. phaffii K51. The proteinase K gene was synthesized and cloned within the plasmid pPICZα-A vector in E. coli TOP10 cells. The proteinase K gene was inserted into pPICZα-A in such a way that – at a subsequent stage of transfection into yeast cells – it was efficiently expressed under the control of the promoter and terminator of the AOX1 gene, and the product of the exogenous gene contained the signal peptide of the Saccharomyces cerevisiae a-factor to ensure the protein’s secretion into the culture medium. The resultant recombinant plasmid (pPICZα-A/PK-w) was transfected into K. phaffii K51 cells. A recombinant K. phaffii K51 clone was obtained that carried the synthetic proteinase K gene and ensured its effective expression and secretion into the culture medium. An approximate productivity of the yeast recombinant clones for recombinant proteinase K was 25 μg/ mL after 4 days of cultivation. The resulting recombinant protease has a high specific proteolytic activity: ~5000 U/mg

Изучение корреляций различных форм простатспецифического антигена и клинико-морфологических характеристик опухолевого процесса у больных раком предст ательной железы

Serum samples from 226 primary patients with prostate cancer (PC) and a baseline total prostate-specific antigen (t-PSA) of < 30.0 ng/ml were used to investigate f-PSA and [-2]proPSA levels and to calculate f-PSA%, [-2]proPSA%, and prostate health index (PHI). The findings were compared with cancer stage (pTNM) and Gleason grade (Gleason index) in accordance with a postoperative histological report. PHI was shown to have the best differentiating properties (pT2c/pT3a/pT3b; localized indolent PC / localized aggressive PC / locally advanced PC / PC with regional metastases; Gleason score 5-6 / Gleason score 7 (3+4) / Gleason score 7 (4+3).В сыворотке крови 226 первичных больных раком предстательной железы (РПЖ) с исходным уровнем общего простатспецифического антигена (общПСА) < 30,0 нг/мл исследованы уровни свободного ПСА (свПСА), [-2]проПСА, высчитаны % свПСА, %[-2] проПСА и индекс здоровья простаты (ИЗП). Полученные данные сопоставлены со стадией опухолевого процесса (pTNM) и степенью злокачественности опухоли по шкале Глисона (индекс Глисона) в соответствии с послеоперационным гистологическим заключением. Показано, что наилучшими дифференцирующими свойствами (pT2c/pT3a/pT3b; локализованный индолентный РПЖ / локализованный агрессивный РПЖ / местно-распространенный РПЖ / РПЖ с регионарными метастазами; индекс Глисона 5–6 / индекс Глисона 7 (3+4) / индекс Глисона 7 (4+3)) обладает ИЗП

Индекс ВИЗГ – новый мультипараметрический показатель для рака предстательной железы

Serum of 336 patients with primary prostate cancer (PC) with baseline total prostate-specific antigen level (totPSA) < 30.0 ng/ml was tested for free PSA (freePSA) and [-2]proPSA; %freePSA, %[-2]proPSA, prostate health index (phi), and a new index APHIG calculated using lab tests and taking into account age, T stage and Gleason score from biopsy were evaluated. Obtained data was compared to tumor stage (pTNM) and malignancy grade according to the Gleason score based on the final histological report after prostatectomy. APHIG has statistically significant benefits compared to PSA-associated markers for differentiation of clinically significant subgroups of PC: pT2c/pT3a/pT3b; local indolent PC/local aggressive/locally advanced/PC with regional metastases; total Gleason score 5–6/7(3 + 4)/7(4 + 3).В сыворотке крови 336 первичных больных раком предстательной железы (РПЖ) с исходным уровнем общего простатического специфического антигена (общПСА) < 30,0 нг/мл исследованы показатели свободного ПСА (свПСА), [-2]проПСА, определены %свПСА, %[-2]проПСА, индекс здоровья предстательной железы (ИЗП) и новый показатель ВИЗГ, рассчитанный на базе лабораторных анализов с учетом возраста, стадии Т и индекса Глисона по результатам биопсии. Полученные данные сопоставлены со стадией опухолевого процесса (pTNM) и степенью злокачественности опухоли по шкале Глисона в соответствии с окончательным гистологическим заключением после проведения простатэктомии. Показано, что ВИЗГ имеет статистически достоверное преимущество перед ПСА-ассоциированными маркерами в дифференцировке клинически значимых подгрупп РПЖ: pT2c/pT3a/pT3b; локализованный индолентный РПЖ/локализованный агрессивный/местно-распространенный/РПЖ с регионарными метастазами; сумма баллов по шкале Глисона 5–6/7(3 + 4)/7(4 + 3)

Определение происхождения природного битума в мумифицирующих смолах древнеегипетских мумий из собрания ГМИИ им. А.С. Пушкина

This work presents the results of a study of the resins of seven Ancient Egyptian mummies from the collection of the Pushkin State Museum of Fine Arts using a complex of analytical methods: gas chromatography, atomic emission and mass spectrometry. Natural bitumen and beeswax were identified in the resins using the gas chromatography–mass spectrometry method. Based on the results of hydrocarbon distribution in the profiles of n-alkanes in the resin coatings of the mummies and naturally occurring bitumen, it was assumed that the Dead Sea bitumen was used. The gas chromatography–mass spectrometry studies of mummy resins in the selected ion mode (m/z 217 and 191) provided additional evidence of the bitumen’s geographic origin. Atomic emission spectrometry with inductively coupled plasma was used as a means to determine the content of microelements. Vanadium, nickel and molybdenum were found in the tar of five mummies. The determined relative amounts of vanadium, nickel, and molybdenum in the resins of the studied mummies showed a good correlation with the available data on the content of these elements in the Dead Sea bitumen, as well as the Fayum mummy resin based on this bitumen. The advantages of using the method of identifying bitumen in mummy resins based on relative content of vanadium, nickel, and molybdenum were revealed.В работе представлены результаты исследования составов смол семи древнеегипетских мумий из коллекции Государственного музея изобразительных искусств имени А.С. Пушкина с применением комплекса аналитических методов: газовой хроматографии (ГХ), атомно-эмиссионной и масс-спектрометрии (МС). Методом ГХ–МС в них идентифицированы природный битум и пчелиный воск. По результатам распределений углеводородов в профилях н-алканов в смоляных покрытиях мумий и природных битумов высказано предположение об использовании битума Мертвого моря. Дополнительные доказательства географического происхождения битума получены ГХ–МС-исследованием смол мумий в режиме мониторинга заданных ионов (m/z 217 и 191). Методом атомно-эмиссионной спектрометрии с индуктивно связанной плазмой определено содержание микроэлементов и показано, что в смолах пяти мумий присутствуют ванадий, никель и молибден. Полученные результаты свидетельствуют об удовлетворительной корреляции их с литературными данными по содержанию указанных элементов в битуме Мертвого моря и смоле Фаюмской мумии на основе этого битума. Выявлены преимущества использования метода идентификации битума в смолах мумий по относительному содержанию ванадия, никеля и молибдена

Итоги первого этапа валидации алгоритма ВИЗГ для уточнения стадирования рака предстательной железы до начала лечения

Background. We have previously described an algorithm APhiGT (Age, Prostate Health index, Gleason score, TNM stage) for staging of prostate cancer (PC) before treatment. The algorithm was developed by logistic regression on an educational selection (ES) of 337 PC cases. The algorithm includes data about the age of patients, the levels of total prostate-specific antigen (PSA), free PSA, [-2]proPSA and the ranked data of the Gleason score (by biopsy results) and T (by TNM).Objective. Validation of APhiGT on the validation selection (VS) of 83 PC cases was carried out in this work.Materials and methods. ROC analysis was performed in ES and VS.Results and сonclusion. It is established that area under the curve (AUC), characterizing the ability to divide clinically significant subgroups of patients (Gleason score <7 vs. Gleason score ≥7, рТ2 vs. рТ3, localized indolent PC vs. localized aggressive PC) for APhiGT both in ES and VS was significantly higher than AUC for total PSA, %[-2]proPSA in free PSA and prostate health index. At the same time, in all clinical subgroups of patients AUC for VS was lower than AUC for ES, which may be due to a significantly smaller size of VS compared to ES.Введение. Ранее нами был описан алгоритм ВИЗГ (Возраст, Индекс Здоровья предстательной железы, сумма баллов по шкале Глисона, стадия TNM) для уточнения стадирования рака предстательной железы (РПЖ) до начала лечения. Алгоритм был разработан путем логистической регрессии на учебной выборке (УВ) из 337 наблюдений РПЖ. В алгоритм входят данные о возрасте пациентов, уровнях общего простатического специфического антигена (общПСА), свободного ПСА, [-2]проПСА и ранжированный показатель суммы баллов по шкале Глисона (по результатам биопсии) и ранжированный показатель Т (по TNMклассификации).Цель исследования – валидация ВИЗГ на валидационной выборке (ВВ) из 83 случаев РПЖ.Материалы и методы. Был проведен ROC-анализ в УВ и ВВ.Результаты и заключение. Установлено, что площадь под ROC-кривой (АUС), характеризующая способность разделять клинически значимые подгруппы больных (сумма баллов по шкале Глисона в соответствии с патоморфологическим заключением <7 / ≥7, рТ2 / рТ3, локализованный индолентный РПЖ / локализованный агрессивный РПЖ) для ВИЗГ как в УВ, так и в ВВ, существенно превосходила АUС для общПСА, доли [-2]проПСА в свободном ПСА и индекса здоровья предстательной железы. В то же время во всех клинических подгруппах больных АUС для ВВ была меньше, чем для УВ, что может быть обусловлено существенно меньшим объемом ВВ по сравнению с УВ.

Валидация пороговых решающих правил и калькулятора для алгоритма ВИЗГ, предназначенного для уточнения стадии рака предстательной железы до начала лечения

Background. We have previously described an algorithm APhiG (Age of patients, Prostate health index and Gleason score), for staging of prostate cancer before treatment. The algorithm was developed by logistic regression on a training dataset and validated on a validation dataset (VD). Objective. Validation of threshold decision rules and a program for APhiG calculation on the VD.Materials and methods. ROC curve analysis on VD (83 cases).Results and conclusion. It was shown that sensitivity, specificity, positive and negative predictive value, diagnostic accuracy threshold decision rules and area under the curve (AUC) for APhiG in the VD (n = 83) not significantly different from those indicators in the training dataset (n = 337), which was the basis for the algorithm APhiG development.Введение. Ранее нами был описан алгоритм ВИЗГ (Возраст, Индекс Здоровья предстательной железы, сумма баллов по шкале Глисона), предназначенный для уточнения стадирования рака предстательной железы (РПЖ) до начала лечения. Алгоритм разработан путем логистической регрессии на учебной выборке и валидирован на валидационной выборке (ВВ) данных.Цель исследования – валидация пороговых решающих правил и программы-калькулятора для алгоритма ВИЗГ на ВВ данных.Материалы и методы. ROC-анализ данных ВВ (n = 83).Результаты и заключение. Показано, что чувствительность, специфичность, положительное и отрицательное прогностические значения, диагностическая точность пороговых решающих правил и площадь под кривой (АUC) для ВИЗГ по результатам ROC-анализа данных ВВ, включающей 83 случая РПЖ, достоверно не отличаются от показателей, рассчитанных по данным учебной выборки, на основании которой был разработан алгоритм ВИЗГ, состоящей из 337 наблюдений РПЖ

СЕРОТИПЫ STREPTOCOCCUS PNEUMONIAE, ВЫЗЫВАЮЩИХ ВЕДУЩИЕ НОЗОЛОГИЧЕСКИЕ ФОРМЫ ПНЕВМОКОККОВЫХ ИНФЕКЦИЙ

First in Russia prospective non-interventional hospital-based study on Streptococcus pneumoniae serotypes causing meningitis and acute otitis media (AOM) in children and community-acquired pneumonia (CAP) in children and adults, as well as serotype coverage by pneumococcal conjugate vaccines (PCV’s) of different composition has been conducted. Serotypes 19F, 14 and serogroup 6 are the leading in meningitis; serotype coverage is 70,6% for PCV7, and 76,5% – for PCV10 and PCV13. Among S. pneumoniae serotypes causing AOM 19F, 3, 23F and serogroup 6 have been the most prevalent in Saint Petersburg. PCV7 and PCV10 provide equal serotypes coverage in AOM – 63,2% among children 0–2 years old, and 32,5% among children 5–17 years old. PCV13 covers up to 79% of serotypes in infants. In CAP PCV7 and PCV10 provide 57,1% serotype coverage in children and 56,1% – in adults. Serotype coverage in CAP for PCV13 has been 14,3% and 34,5% higher for children and adults, correspondingly. Obtained data supports PCV inclusion in children immunization program in Saint Petersburg, whereas PCV13 provides the broadest serotype coverage. In the course PCV’s implementation continued pneumococcal infection surveillance is advisable.Впервые в России в проспективном неинтервенционном госпитальном эпидемиологическом исследовании изучен серотиповой состав Streptococcus pneumoniae, вызывающих менингиты, внебольничную пневмонию и острый средний отит (ОСО), а также охват циркулирующих серотипов пневмококковыми конъюгированными вакцинами (ПКВ) различного состава. К ведущим серотипам S. pneumoniae, вызывающим у детей гнойный менингит, относятся 19F, 14 и серогруппа 6. Охват серотипов S. pneumoniae, вызывающих гнойный менингит для ПКВ7, составляет 70,6%, а для ПКВ10 и ПКВ13 – 76,5%. Ведущими серотипами пневмококков, вызывающих ОСО, в Санкт-Петербурге являются серотипы 19F, 3, 23F и серогруппа 6. Охват серотипов для ПКВ7 и ПКВ10 одинаков и составляет 63,2% для детей в возрасте 0–2 лет и 32,5% для детей в возрасте 5–17 лет. Для ПКВ13 эти показатели составляют соответственно 79% и 55%. При внебольничной пневмонии ПКВ7 и ПКВ10 обеспечивали одинаковый охват: 57,1% у детей и 56,1% у взрослых. Для ПКВ13 эти показатели были на 14,3% больше у детей и на 34,5% у взрослых. Полученные данные обосновывают целесообразность применения пневмококковых конъюгированных вакцин для массовой иммунизации детей в Санкт-Петербурге, при этом ПКВ13 обеспечивает наибольший охват серотипов S. pneumoniae, вызывающих основные пневмококковые заболевания. Для оценки эффективности вакцинации целесообразно продолжить эпидемиологическое наблюдение за пневмококковыми инфекциями после проведения массовой иммунизации ПКВ13

Session 17 Ecophysiology

n/

EPMA-World Congress 2015: Bonn, Germany. 3-5 September 2015

Table of contents A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma Jella-Andrea Abraham, Olga Golubnitschaja A2 Integrated market access approach amplifying value of “Rx-CDx” Ildar Akhmetov A3 Disaster response: an opportunity to improve global healthcare Russell J. Andrews, Leonidas Quintana A4 USA PPPM: proscriptive, profligate, profiteering medicine-good for 1 % wealthy, not for 99 % unhealthy Russell J. Andrews A5 The role of IDO in a murine model of gingivitis: predictive and therapeutic potentials Babak Baban, Jun Yao Liu, Xu Qin, Tailing Wang, Mahmood S. Mozaffari A6 Specific diets for personalised treatment of diabetes type 2 Viktoriia V. Bati, Tamara V. Meleshko, Olga B. Levchuk, Nadiya V. Boyko A7 Towards personalized physiotherapeutic approach Joanna Bauer, Ewa Boerner, Halina Podbielska A8 Cells, animal, SHIME and in silico models for detection and verification of specific biomarkers of non-communicable chronic diseases Alojz Bomba, Viktor O. Petrov, Volodymyr G. Drobnych, Rostyslav V. Bubnov, Oksana M. Bykova, Nadiya V. Boyko A9 INTERACT-chronic care model: Self-treatment by patients with decision support e-Health solution Hans-Peter Brunner-La Rocca, Lutz Fleischhacker, Olga Golubnitschaja, Frank Heemskerk, Thomas Helms, Tiny Jaarsma, Judita Kinkorova, Jan Ramaekers, Peter Ruff, Ivana Schnur, Emilio Vanoli, Jose Verdu A10 PPPM in cardiovascular medicine in 2015 Hans-Peter Brunner-La Rocca A11 Magnetic resonance imaging of nanoparticles in mice, potential for theranostic and contrast media development – pilot results Rostyslav V. Bubnov, Sergiy A. Grabovetskyi, Olena M. Mykhalchenko, Natalia O. Tymoshok, Oleksandr B. Shcherbakov, Igor P. Semeniv, Mykola Y. Spivak A12 Ultrasound diagnosis for diabetic neuropathy - comparative study Rostyslav V. Bubnov, Tetyana V. Ostapenko A13 Ultrasound for stratification patients with diabetic foot ulcers for prevention and personalized treatment - pilot results Rostyslav V. Bubnov, Nazarii M. Kobyliak, Nadiya M. Zholobak, Mykola Ya. Spivak A14 Project ImaGenX – designing and executing a questionnaire on environment and lifestyle risk of breast cancer John Paul Cauchi A15 Genomics – a new structural brand of predictive, preventive and personalized medicine or the new driver as well? Dmitrii Cherepakhin, Marina Bakay, Artem Borovikov, Sergey Suchkov A16 Survey of questionnaires for evaluation of the quality of life in various medical fields Barbara Cieślik, Agnieszka Migasiewicz, Maria-Luiza Podbielska, Markus Pelleter, Agnieszka Giemza, Halina Podbielska A17 Personalized molecular treatment for muscular dystrophies Sebahattin Cirak A18 Secondary mutations in circulating tumour DNA for acquired drug resistance in patients with advanced ALK + NSCLC Marzia Del Re, Paola Bordi, Valentina Citi, Marta Palombi, Carmine Pinto, Marcello Tiseo, Romano Danesi A19 Recombinant species-specific FcεRI alpha proteins for diagnosis of IgE-mediated allergies in dogs, cats and horses Lukas Einhorn, Judit Fazekas, Martina Muhr, Alexandra Schoos, Lucia Panakova, Ina Herrmann, Krisztina Manzano-Szalai, Kumiko Oida, Edda Fiebiger, Josef Singer, Erika Jensen-Jarolim A20 Global methodology for developmental neurotoxicity testing in humans and animals early and chronically exposed to chemical contaminants Arpiné A. Elnar, Nadia Ouamara, Nadiya Boyko, Xavier Coumoul, Jean-Philippe Antignac, Bruno Le Bizec, Gauthier Eppe, Jenny Renaut, Torsten Bonn, Cédric Guignard, Margherita Ferrante, Maria Liusa Chiusano, Salvatore Cuzzocrea, Gerard O'Keeffe, John Cryan, Michelle Bisson, Amina Barakat, Ihsane Hmamouchi, Nasser Zawia, Anumantha Kanthasamy, Glen E. Kisby, Rui Alves, Oscar Villacañas Pérez, Kim Burgard, Peter Spencer, Norbert Bomba, Martin Haranta, Nina Zaitseva, Irina May, Stéphanie Grojean, Mathilde Body-Malapel, Florencia Harari, Raul Harari, Kristina Yeghiazaryan, Olga Golubnitschaja, Vittorio Calabrese, Christophe Nemos, Rachid Soulimani A21 Mental indicators at young people with attributes hypertension and pre-hypertension Maria E. Evsevyeva, Elena A. Mishenko, Zurida V. Kumukova, Evgeniy V. Chudnovsky, Tatyana A. Smirnova A22 On the approaches to the early diagnosis of stress-induced hypertension in young employees of State law enforcement agencies Maria E. Evsevyeva, Ludmila V. Ivanova, Michail V. Eremin, Maria V. Rostovtseva A23 Сentral aortic pressure and indexes of augmentation in young persons in view of risk factors Maria E. Evsevyeva, Michail V. Eremin, Vladimir I. Koshel, Oksana V. Sergeeva, Nadesgda M. Konovalova A24 Breast cancer prediction and prevention: Are reliable biomarkers in horizon? Shantanu Girotra, Olga Golubnitschaja A25 Flammer Syndrome and potential formation of pre-metastatic niches: A multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease Olga Golubnitschaja, Manuel Debald, Walther Kuhn, Kristina Yeghiazaryan, Rostyslav V. Bubnov, Vadym M. Goncharenko, Ulyana Lushchyk, Godfrey Grech, Katarzyna Konieczka A26 Innovative tools for prenatal diagnostics and monitoring: improving individual pregnancy outcomes and health-economy in EU Olga Golubnitschaja, Jan Jaap Erwich, Vincenzo Costigliola, Kristina Yeghiazaryan, Ulrich Gembruch A27 Immunohistochemical assessment of APUD cells in endometriosis Vadym M. Goncharenko, Vasyl O. Beniuk, Olga V. Kalenska, Rostyslav V. Bubnov A28 Updating personalized management algorithm of endometrial hyperplasia in pre-menopause women Vadym M. Goncharenko, Vasyl O. Beniuk, Rostyslav V. Bubnov, Olga Melnychuk A29 The personified treatment approach of polimorbid patients with periodontal inflammatory diseases Irina A. Gorbacheva, Lyudmila Y. Orekhova, Vadim V. Tachalov A30 Ukrainian experience in hybrid war – the challenge to update algorithms for personalized care and early prevention of different military injuries Olena I. Grechanyk, Rizvan Ya. Abdullaiev, Rostyslav V. Bubnov A31 Tear fluid biomarkers: a comparison of tear fluid sampling and storage protocols Suzanne Hagan, Eilidh Martin, Ian Pearce, Katherine Oliver A32 The correlation of dietary habits with gingival problems during menstruation Cenk Haytac, Fariz Salimov, Servin Yoksul, Anatoly A. Kunin, Natalia S. Moiseeva A33 Genomic medicine in a contemporary Spanish population of prostate cancer: our experience Bernardo Herrera-Imbroda, Sergio del Río-González, Maria Fernanda Lara, Antonia Angulo, Francisco Javier Machuca Santa-Cruz A34 Challenges, opportunities and collaborations for personalized medicine applicability in uro-oncological disease Bernardo Herrera-Imbroda, Sergio del Río-González, Maria Fernanda Lara A35 Metabolic hallmarks of cancer as targets for a personalized therapy John Ionescu A36 Influence of genetic polymorphism as a predictor of the development of periodontal disease in patients with gastric ulcer and 12 duodenal ulcer Alfiya Z. Isamulaeva, Anatoly A. Kunin, Shamil Sh. Magomedov, Aida I. Isamulaeva A37 Challenges in diabetic macular edema Tatjana Josifova A38 Overview of the EPMA strategies in laboratory medicine relevant for PPPM Marko Kapalla, Juraj Kubáň, Olga Golubnitschaja, Vincenzo Costigliola A39 EPMA initiative for effective organization of medical travel: European concepts and criteria Vincenzo Costigliola, Marko Kapalla, Juraj Kubáň, Olga Golubnitschaja A40 Design and innovation in e-textiles: implications for PPPM Anthony Kent, Tom Fisher, Tilak Dias A41 Biobank in Pilsen as a member of national node BBMRI_CZ Judita Kinkorová, Ondřej Topolčan A42 Big data in personalized medicine: hype and hope Matthias Kohl A43 The 3P approach as the platform of the European Dentistry Department (DPPPD) Anatoly A. Kunin, Natalia S. Moiseeva A44 The endometrium cytokine patterns for predictive diagnosis of proliferation severity and cancer prevention Andrii I. Kurchenko, Vasyl A. Beniuk, Vadym M. Goncharenko, Rostyslav V. Bubnov, Nadiya V. Boyko, Andriy M. Strokan A45 A monocyte-based in-vitro system for testing individual responses to the implanted material: future for personalized implant construction Julia Kzhyshkowska, Alexandru Gudima, Ksenia S. Stankevich, Victor D. Filimonov4, Harald Klüter, Evgeniya M. Mamontova, Sergei I. Tverdokhlebov A46 Prediction and prevention of adverse health effects by meteorological factors: Biomarker patterns and creation of a device for self-monitoring and integrated care Ulyana B. Lushchyk, Viktor V. Novytskyy, Igor P. Babii, Nadiya G. Lushchyk, Lyudmyla S. Riabets, Ivanna I. Legka A47 Targeting "disease signatures" towards personalized healthcare Mira Marcus-Kalish, Alexis Mitelpunkt, Tal Galili, Neta Shachar, Yoav Benjamini A48 Influence of the skin imperfection on the personal quality of life and possible tools for objective diagnosis Agnieszka Migasiewicz, Markus Pelleter, Joanna Bauer, Ewelina Dereń, Halina Podbielska A49 The new direction in caries prevention based on the ultrastructure of dental hard tissues and filling materials Natalia S. Moiseeva, Anatoly A. Kunin, Dmitry A. Kunin A50 The use of LED radiation in prevention of dental diseases Natalia S. Moiseeva, Yury A. Ippolitov, Dmitry A. Kunin, Alexei N. Morozov, Natalia V. Chirkova, Nakhid T. Aliev A51 Status of endothelial progenitor cells in diabetic nephropathy: predictive and preventive potentials Mahmood S. Mozaffari, Jun Yao Liu, Babak Baban A52 The status of glucocorticoid-induced leucine zipper protein in salivary gland in Sjögren’s syndrome: predictive and personalized treatment potentials Mahmood S. Mozaffari, Jun Yao Liu, Rafik Abdelsayed, Xing-Ming Shi, Babak Baban A53 Maximal aerobic capacity - important quality marker of health Jaroslav Novák, Milan Štork, Václav Zeman A54 The EMPOWER project: laboratory medicine and Horizon 2020 Wytze P. Oosterhuis, Elvar Theodorsson A55 Personality profile manifestations in patient’s attitude to oral care and adherence to doctor’s prescriptions Lyudmila Y. Orekhova, Tatyana V. Kudryavtseva, Elena R. Isaeva, Vadim V. Tachalov, Ekaterina S. Loboda A56 Results of an European survey on personalized medicine addressed to directions of laboratory medicine Mario Pazzagli, Francesca Malentacchi, Irene Mancini, Ivan Brandslund, Pieter Vermeersch, Matthias Schwab, Janja Marc, Ron H.N. van Schaik, Gerard Siest, Elvar Theodorsson, Chiara Di Resta A57 MCI or early dementia predictive speech based diagnosis techniques Matus Pleva, Jozef Juhar A58 Personalized speech based mobile application for eHealth Matus Pleva, Jozef Juhar A59 Circulating tumor cell-free DNA as the biomarker in the management of cancer patients Jiří Polívka jr., Filip Janků, Martin Pešta, Jan Doležal, Milena Králíčková, Jiří Polívka A60 Complex stroke care – educational programme in Stroke Centre University Hospital Plzen Jiří Polívka, Alena Lukešová, Nina Müllerová, Petr Ševčík, Vladimír Rohan A61 Sleep apnea and sleep fragmentation contribute to brain aging Kneginja Richter, Lence Miloseva, Günter Niklewski A62 Personalised approach for sleep disturbances in shift workers Kneginja Richter, Jens Acker, Guenter Niklewski A63 Medical travel and innovative PPPM clusters: new concept of integration Olga Safonicheva, Vincenzo Costigliola A64 Medical travel and women health Olga Safonicheva A65 Continuity of generations in the training of specialists in the field of reconstructive microsurgery Maxim Sautin, Janna Sinelnikova, Sergey Suchkov A66 Telemonitoring of stroke patients – empirical evidence of individual risk management results from an observational study in Germany Songül Secer, Stephan von Bandemer A67 Women’s increasing breast cancer risk with n-6 fatty acid intake explained by estrogen-fatty acid interactive effect on DNA damage: implications for gender-specific nutrition within personalized medicine Niva Shapira A68 Cytobacterioscopy of the gingival crevicular fluid as a method for preventive diagnosis of periodontal diseases Aleksandr Shcherbakov, Anatoly A. Kunin, Natalia S. Moiseeva A69 Use of specially treated composites in dentistry to avoid violations of aesthetics Bogdan R. Shumilovich, Zhanna Lipkind, Yulia Vorobieva, Dmitry A. Kunin, Anastasiia V. Sudareva A70 National eHealth system – platform for preventive, predictive and personalized diabetes care Ivica Smokovski, Tatjana Milenkovic A72 The common energy levels of Prof. Szent-Györgyi, the intrinsic chemistry of melanin, and the muscle physiopathology. Implications in the context of Preventive, Predictive, and Personalized Medicine Arturo Solís-Herrera, María del Carmen Arias-Esparza, Sergey Suchkov A73 Plurality and individuality of hepatocellular carcinoma: PPPM perspectives Krishna Chander Sridhar, Olga Golubnitschaja A74 Strategic aspects of higher medical education reforms to secure newer educational platforms for getting biopharma professionals matures Maria Studneva, Sihong Song, James Creeden, Мark Мandrik, Sergey Suchkov A75 Overview of the strategies and activities of the European Federation of Clinical Chemistry and Laboratory Medicine, (EFLM) Elvar Theodorsson, EFLM A76 New spectroscopic techniques for point of care label free diagnostics Syed A. M. Tofail A77 Tumor markers for personalized medicine and oncology - the role of Laboratory Medicine Ondřej Topolčan, Judita Kinkorová, Ondřej Fiala, Marie Karlíková, Šárka Svobodová, Radek Kučera, Radka Fuchsová, Vladislav Třeška, Václav Šimánek, Ladislav Pecen, Jan Šoupal, Štěpán Svačina2 A78 Modern medical terminology (MMT) as a driver of the global educational reforms Evgeniya Tretyak, Maria Studneva, Sergey Suchkov A79 Juvenile hypertension; the relevance of novel predictive, preventive and personalized assessment of its determinants Francesca M. Trovato, G. Fabio Martines, Daniela Brischetto, Daniela Catalano, Giuseppe Musumeci, Guglielmo M. Trovato A80 Proteomarkers Biotech George Th. Tsangaris, Athanasios K. Anagnostopoulos A81 Proteomics and mass spectrometry based non-invasive prenatal testing of fetal health and pregnancy complications George Th. Tsangaris, Athanasios K. Anagnostopoulos A82 Integrated Ecosystem for an Integrated Care model for Heart Failure (HF) patients including related comorbidities (ZENITH) José Verdú, German Gutiérrez, Jordi Rovira, Marta Martinez, Lutz Fleischhacker, Donna Green, Arthur Garson, Elena Tamburini, Stefano Cuomo, Juan Martinez-Leon, Teresa Abrisqueta, Hans-Peter Brunner-La Rocca, Tiny Jaarsma, Teresa Arredondo, Cecilia Vera, Giuseppe Fico, Olga Golubnitschaja, Fernando Arribas, Martina Onderco, Isabel Vara, on behalf of ZENITH consortium A83 Predictive, preventive and personalized medicine in diabetes onset and complication (MOSAIC project) José Verdú, Francesco Sambo, Barbara Di Camillo, Claudio Cobelli, Andrea Facchinetti, Giuseppe Fico, Riccardo Bellazzi, Lucia Sacchi, Arianna Dagliati, Daniele Segnani, Valentina Tibollo, Manuel Ottaviano, Rafael Gabriel, Leif Groop, Jacqueline Postma, Antonio Martinez, Liisa Hakaste, Tiinamaija Tuomi, Konstantia Zarkogianni, on behalf of MOSAIC consortium A84 Possibilities for personalized therapy of diabetes using in vitro screening of insulin and oral hypoglycemic agents Igor Volchek, Nina Pototskaya, Andrey Petrov A85 The innovative technology for personalized therapy of human diseases based on in vitro drug screening Igor Volchek, Nadezhda Pototskaya, Andrey Petrov A86 Bone destruction and temporomandibular joint: predictive markers, pathogenetic aspects and quality of life Ülle Voog-Oras, Oksana Jagur, Edvitar Leibur, Priit Niibo, Triin Jagomägi, Minh Son Nguyen, Chris Pruunsild, Dagmar Piikov, Mare Saag A87 Sub-optimal health management – global vision for concepts in medical travel Wei Wang A88 Sub-optimal health management: synergic PPPM-TCAM approach Wei Wang A89 Innovative technologies for minimal invasive diagnostics Andreas Weinhäusel, Walter Pulverer, Matthias Wielscher, Manuela Hofner, Christa Noehammer, Regina Soldo, Peter Hettegger, Istvan Gyurjan, Ronald Kulovics, Silvia Schönthaler, Gabriel Beikircher, Albert Kriegner, Stephan Pabinger, Klemens Vierlinger A90 Rare disease diobanks for personalized medicine Ayşe Yüzbaşıoğlu, Meral Özgüç, Member of EuroBioBank - European Network of DNA, Cell and Tissue Banks for Rare Disease